sábado, 14 de novembro de 2026
PesquisarExplore
pt.via.news
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· December 24, 2025

Is JPMorgan Stock a Buy for 2026 as it Hits an All-Time High?

View original at finance.yahoo.com
Is JPMorgan Stock a Buy for 2026 as it Hits an All-Time High? JPMorgan’s JPM shares reached a new all-time high of $327.78 yesterday, driven by optimism for the easing rate cycle and stronger U.S…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Consensus mark for 2025 and 2026 revenues suggests a year-over-year rise of 2.8% and 3.9%, respectively

    80% confidence

  • JPMorgan remains well-placed for growth in 2026, backed by its robust capital markets business, dominant IB position, decent NII growth expectations and continued expansion through branch openings

    80% confidence

  • NII expected to rise 6-7% in 2025

    80% confidence

  • JPMorgan is mulling entry into the crypto trading business

    80% confidence

  • 2026 non-interest expenses expected to rise by more than $9 billion to $105 billion

    80% confidence

  • NII (excluding Markets) expected to grow 5.5%

    80% confidence

  • NII (excluding Markets) expected to be nearly $92.2 billion in 2025 and $95 billion in 2026

    80% confidence

  • Zacks Consensus Estimate for earnings implies 2.9% and 3.5% year-over-year growth for 2025 and 2026, respectively

    80% confidence
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Late-2026 Biotech Catalyst Season: FDA Decisions and Pivotal Readouts Converge Across Oncology, Hepatology and Cardiometabolic
Mid-November 2026 is dense with scheduled biotech catalysts. The ivonescimab BLA PDUFA date is 2026-11-14, the lorundrostat PDUFA date is 2026-12-22, and Phase 3 ECLIPSE hepatitis delta data are due in Q1 2027. Alongside these, siRNA and antibody programs (plozasiran, elebsiran/tobevibart, ianalumab, nipocalimab) reported or presented data at AHA, AASLD, ACR and ASH, while Oryzon advanced iadademstat in AML with Spanish trial authorizations and a planned ALICE-3 Phase III. Late-stage data and regulatory milestones are driving the sentiment. A planned delisting (EGM 2026-11-19, application 2027-01-25) is a separate corporate-structure event with no clear link to the rest.
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,995
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,995 factos verificados com a fonte5,580 documentos-fonte arquivados
Consulte estes dados → isubstrate.com
Is JPMorgan Stock a Buy for 2026 as it Hits an All-Time High? — Source | Via News | pt.via.news